6^th World Congress on Cell & Stem Cell Research February 29-March 02, 2016 Philadelphia, Pennsylvania, USA

Haval Shirwan is Dr. Michael and Joan Hamilton Endowed Chair in Autoimmune Disease, Professor of Microbiology and Immunology, Director of Molecular Immunomodulation Program at the Institute for Cellular Therapeutics. He conducted his Graduate studies at the University of California in Santa Barbara, CA, and Postdoctoral studies at California Institute of Technology in Pasadena, CA. He joined the University of Louisville in 1998 after holding academic appointments at various academic institutions in the United States. He is member of several national and international societies and recipient of various awards.

His research focuses on the modulation of immune system for the treatment of immune-based diseases with particular focus on type 1 diabetes, transplantation, and development of prophylactic and therapeutic vaccines against cancer and infectious diseases. He is an inventor on over a dozen of worldwide patents, widely published, organized and lectured at numerous national/international conferences, served on study sections for various federal and non-profit funding agencies, and is on the Editorial Board of a dozen of scientific journals.

Davis is a graduate of Harvard Medical School and had his postgraduate medical training at Albert Einstein College of Medicine and the NIH. His academic positions have included Chair, Department of Medicine, Albany Medical College. He has served as President, American Thyroid Association, as a member of the Board of Directors of the American Board of Internal Medicine and he is Co-Head, Faculty of 1000 – Endocrinology. He serves on multiple Editorial Boards of His scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He and his colleagues described the cell surface receptor for thyroid hormone on integrin v3 that underlies the pro-angiogenic activity of the hormone and the proliferative action of the hormone on cancer cells. He has co-authored more than 200 original research articles and 30 textbook chapters and he has edited three medical textbooks.

Paul J. Davis's scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He and his colleagues described the cell surface receptor for thyroid hormone on integrin v3 that underlies the pro-angiogenic activity of the hormone and the proliferative action of the hormone on cancer cells

Drapeau holds a Bachelor’s degree in Honors Neurophysiology and a Master’s degree in Neurology and Neurosurgery from Canada’s McGill University in Montreal, Quebec, with work performed at the Montreal Neurological Institute. His thesis was on epileptogenesis and the role of eicosanoids in long-term potentiation and he completed further scientific training in variable projection microscopy at Bradford Research Institute and in ion-selective microelectrode recordings at St-Anne Hospital in France. Mr. Drapeau has been the Director of Research and Development at Cell Tech International and then Desert Lake Technologies, before co-founding STEMTech HealthSciences and becoming its Chief Science Officer. He is the author of the Stem Cell Theory of Renewal, detailed in his book Cracking the Stem Cell Code.

His interest focuses on basic and clinical research pertaining to adult stem cells, and more specifically the natural role of stem cells in the body and clinical potential of Endogenous Stem Cell Mobilization (ESCM).

Herrera is currently Chair of Pathology and Laboratory Director of LSU Health Shreveport, a position he has held from 1996-2006 and since 2012 until now. He is an internationally renowned nephropathologist with over 35 years of experience in renal pathology. Having received his Doctor of Medicine at the University of Puerto Rico, he has over 30 years of research on renal damage associated with multiple myeloma. Before becoming the Chair of Pathology of LSU Health Shreveport, Dr. Herrera was the Medical Director of Nephrocor, a private renal pathology laboratory. He has served as Professor and Chair at St. Louis University as well as Director of Surgical Pathology at both the University of Alabama and the University of Mississippi. Dr. Herrera is a retired Colonel with the U.S. Army. He is also a Professor in the Department of Anatomy and Cell Biology at LSU Health in Shreveport

Herrera sits on multiple national panels and has been the invited guest lecturer in over 300 domestic and international venues. He has authored more than 280 articles and chapters. His main interest includes understanding of pathogenesis of renal disorders occurring in patients with plasma cell dyscrasias and has engaged in exploring glomerular repair using stem cells. He has received the “Tatiana T. Antovych, M.D. Award” from the Armed Forces Institute of Pathology/American Registry of Pathology for contributions to renal pathology. He is the recipient of a grant from the Amyloidosis Foundation to study glomerular repair in AL-amyloidosis using mesenchymal stem cells.

Simon Berkovich received MS in Applied Physics from Moscow Physical-Technical Institute (1960) and PhD in Computer Science from the Institute of Precision Mechanics and Computer Technology of the USSR Academy of Sciences (1964). He played a leading role in a number of advanced computer systems projects. He has several hundred publications in various areas of physics, electronics, computer science, and biology. In 2002, Professor Simon Berkovich was elected a member of the European Academy of Sciences "for an outstanding contribution to computer science and the development of fundamental computational algorithms". In 2014, he won the GWU Technology Transfer Innovation Competition.

He has several hundred publications in various areas of physics, electronics, computer science, and biology. In 2002, Professor Simon Berkovich was elected a member of the European Academy of Sciences "for an outstanding contribution to computer science and the development of fundamental computational algorithms". In 2014, he won the GWU Technology Transfer Innovation Competition.

Dennis M. Lox M.D is the Director of the Sports and Regenerative Medicine Centers A Stem Cell Center of Excellence in the Washington D.C. Metro Area and the Tampa Bay Metro Area. Dr. Lox attended the University of Arizona, where he was Phi Beta Kappa studying Liberal Arts. Dr. Lox then completed his medical training at Texas Tech University, followed by his residency program in PM&R at The University of Texas Health Science Centers at San Antonio. Dr. Lox has always pursued Sports Medicine, and this led to a path into Regenerative Medicine.

Lox has always pursued Sports Medicine, and this led to a path into Regenerative Medicine.

Diana Anderson completed her PhD in the Faculty of Medicine University of Manchester, UK. She currently holds the Established Chair in Biomedical Sciences at the University of Bradford. She has published over 450 papers and eight books. She has served on 10 editorial boards, has supervised 30 PhD students and is Editor- in- Chief of the Book Series “Issues in Toxicology” for the Royal Society of Chemistry. She has hosted and participated in 56 meetings for the WHO on Chemical Safety. She has been a Vice President of the Institute of Biology.

cancer, oxygen radicals, human biomonitoring, unbalanced precursor pools, dietary imbalance, male-mediated developmental defects, nanotoxicology, general toxicology

Gallicchio earned his Ph.D. in Experimental Hematology at New York University Medical Center. He completed a fellowship in hematology at Memorial Sloan Kettering and Did post--‐graduate training at the University Of Connecticut Health Center. He received his Diploma in internal medicine from the “Vasile Goldis” University of Arad (Romania). He has published more than 160 scientific articles and book chapters and has received ten U.S. patents for discoveries focused on drug development for AIDS and cancer. He has served on the faculty of several American and international universities in Addition to serving as President of Alpha Eta Honor Society, the International Society For Lithium Research, and the International Federation of Biomedical Laboratory Science. He currently serves as Vice President, Educational and Research Centers in Trace Elements operated under UNESCO. He is a Fellow of the Association of Clinical Scientists, the Association of Schools of Allied Health Professions, and the Royal Society Of the Arts. In 2003, at the 200th anniversary of RSA, because of his long--‐standing effort To educate and train biomedical laboratory scientists from England, Dr. Gallicchio was recognized for his efforts by being presented to Her Majesty, Queen Elizabeth II.

Research interests include experimental drug therapeutics for AIDS and cancer with a focus on compounds that inhibit ribonucleotide reductase and anti-oxidants derived from natural food products; the non-psychiatric clinical uses of lithium, in particular for Alzheimer's disease and viral-induced pathogens; experimantal hematopoiesis, with a particular interest in stem cell biology and the role of stroma/microenvironment in these processes; international education pertaining to biomedical laboratory science.

Georg F. Weber attended medical school in Wuerzburg, Germany. He worked at the Dana-Farber Cancer Institute, Harvard Medical School from 1990 through 1999 and is currently on the faculty at the University of Cincinnati. Georg F. Weber has published close to 90 scientific reports, including many in the most respected professional journals, and various monographs, most recently textbooks on molecular oncology and anti-cancer drugs. He holds several patents.

Weber has made contributions to metastasis research by discovering the interaction between the molecules osteopontin and CD44 and by defining the physiologic role of metastasis genes as stress response genes. While he continues to address fundamental questions, he is researching new venues for diagnosis and therapy of cancer progression.

Khalid Shah is an Associate Professor at Harvard Medical School and directs the Molecular Neurotherapy and Imaging Laboratory at Massachusetts General Hospital in Boston, MA. He is also the Director of the Stem Cell Therapeutics and Imaging program in MGH's Center for Translational Research, and is a Principal Faculty at Harvard Stem Cell Institute in Boston. Dr. Shah's recently published works are two books featuring current groundbreaking insights into stem cell therapies for cancer, Stem Cell Therapeutics for Cancer (Wiley-Blackwell 2013), and Mesenchymal Stem Cells in Cancer Therapy (Elsevier 2014). The potential of developing novel cancer therapies by him and his team has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from Alliance for cancer gene therapy (ACGT), Research fellow award from American Cancer Society (ACS), Distinguished research award from Academy of Radiology and Innovation awards from James McDonnell Foundation, American Brain Tumor Association (ABTA) and Goldhirsh foundation. Additionally, Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who recently awarded him the Harvard Young Mentor Award.

In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy.

Xiao is a Professor and the scientific Director in School of Pharmaceutical Sciences and Technology at Dalian University of Technology, and the Director of the Functional Genomics and Proteomics Laboratories at the Creighton University School of Medicine, and an internationally recognized expert in the field of genomics and proteomics of cancer. Dr. Xiao earns his Ph.D. in molecular computational biology at Chinese Academy of Sciences.

Xiao had his postdoctoral research trained in Baylor College of Medicine and UCLA, focusing on pharmacokinetics and biochemistry of non-steroid inflammatory drugs, and cell cycle regulation. He has been regular reviewer or ad hoc reviewer for several medical journals, different funding agency and several journal Editorial Board members and senior Editors.

George G Chen is a professor in the Department of Surgery, Director of Surgical Research Laboratories, the Chinese University of Hong Kong, Hong Kong, China. He is also served as a principle investigator at the Hong Kong Cancer Institute. He has authored or co-authored ~120 papers and has written a number of books or book chapters. He is currently a member of editorial boards or a guest editor of a number of scientific journals and a regular peer-reviewer for several grant agents. He was educated in China and United Kingdom and has MB and PhD degrees.

He has extensive experience in cancer research, particularly in the area of apoptosis in hepatocellular carcinoma, lung caner and thyroid cancer.